OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+8.8%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$95M
AUM Growth
+$95M
(-6.5%)
Cap. Flow
-$5.81M
Cap. Flow
% of AUM
-6.11%
Top 10 Holdings %
Top 10 Hldgs %
53.5%
Holding
63
New
2
Increased
1
Reduced
29
Closed
2
Top Buys
| 1 |
iShares Biotechnology ETF
IBB
|
$2.67M |
| 2 |
ProQR Therapeutics
PRQR
|
$992K |
| 3 |
FibroGen
FGEN
|
$210K |
Top Sells
| 1 |
Direxion Daily S&P Biotech Bull 3X Shares
LABU
|
$1.37M |
| 2 |
Nektar Therapeutics
NKTR
|
$732K |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$558K |
| 4 |
Neurocrine Biosciences
NBIX
|
$422K |
| 5 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$417K |
Sector Composition
| 1 | Healthcare | 80.2% |
| 2 | Real Estate | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SCTL
51
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $233K | 0.2% | 25,231 | – | – |
|
|
ICPT
52
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $221K | 0.19% | 3,779 -702 | -16% | -$41.1K |
|
53
Gilead Sciences
GILD
$140B
| $220K | 0.19% | 3,075 -3,387 | -52% | -$242K |
|
|
54
FibroGen
FGEN
$47.8M
| $210K | 0.18% | +4,423 | New | +$210K |
|
55
Acadia Pharmaceuticals
ACAD
$4.38B
| $207K | 0.18% | 6,880 -8,759 | -56% | -$264K |
|
56
Precigen
PGEN
$1.34B
| $164K | 0.14% | 14,221 -9,707 | -41% | -$112K |
|
57
SCYNEXIS
SCYX
$34.9M
| $155K | 0.13% | 66,608 | – | – |
|
|
CFRX
58
DELISTED
ContraFect Corporation
CFRX
| $152K | 0.13% | 150,000 | – | – |
|
|
PGNX
59
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $130K | 0.11% | 21,782 | – | – |
|
|
60
Direxion Daily S&P Biotech Bull 3X Shares
LABU
$647M
| – | – | -16,002 | Closed | -$1.37M |
|
61
Ligand Pharmaceuticals
LGND
$3.15B
| – | – | -1,519 | Closed | -$207K |
|
62
Eli Lilly
LLY
$657B
| – | – | 0 | – | – |
|
|
SAGE
63
DELISTED
Sage Therapeutics
SAGE
| – | – | 0 | – | – |
|